Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Antares: Pipeline is Bursting with Late Stage Products (ATRS, $2.77, Buy)

Key Points:

Antares has an impressive portfolio of seven new products that could lead to explosive growth over the next…
Read more…

AMAG Pharmaceuticals: Will FDA Approve Makena SC (AMAG, Neutral, $21.75)

Importance of Makena SC to AMAG?

AMAG is engaged in a high stakes clinical development program in which it is endeavoring…
Read more…

AMAG and Antares: Update on the Development of Makena SC (AMAG, Neutral, $24.40) (ATRS, Buy, $2.04)

Key Points:

Recent announcement that AMAG will not pursue Orphan Drug Exclusivity for Makena SC has hammered the stock of…
Read more…

Antares: Teva Projects Launch of AB Rated Generic to EpiPen in Early 2018 (ATRS, Buy, $1.87)

Eyal Desheh is the Chief Financial Officer of Teva. During the recent third quarter conference call, he answered a question…
Read more…

Antares: Some Key Points from 3Q, 2016 Conference Call (ATRS, Buy, $1.84)

Investment Opinion

In my opinion, Antares is substantially undervalued. My price target is $6 60 in 2018. The thinking behind this…
Read more…

Antares: Updates on QST and AB Generic to EpiPen; Reiteration of Buy Recommendation (ATRS, Buy, $1.65)

Overview and Investment Opinion

In my opinion, Antares is substantially undervalued. My price target is $6 60 $8 in 2018 and…
Read more…

Antares; Are Mylan's Woes A Potential Positive for AB Rated Generic to EpiPen (ATRS, $1.37, Buy)

You cannot turn on the business news channels without hearing extensive comments and condemnation by pundits and politicians about Mylan's aggressive…
Read more…

Antares: Comment on Strength in the Stock Price (ATRS, $1.29, Buy)

A number of people have asked me if I know of any specific reason for the strength in Antares's stock…
Read more…

Antares Pharmaceuticals: Teva Launches AB Generic to Imitrex (ATRS, Buy, $1.06)

Teva announced today the launch of its AB rated generic to Imitex (sumatriptan). Remember that Antares books revenues from Teva…
Read more…

Antares Pharmaceuticals: Highlights on Makena from AMAG Pharmaceuticals Analyst Day (ATRS, $1.14, Buy)

Report Overview

Antares and AMAG Pharmaceuticals are jointly developing a new subcutaneous formulation of AMAG’s key drug Makena which is currently…
Read more…

Antares: Presentation Highlights from Deutsche Bank Conference (ATRS, Buy, $0.97)

Overview

I listened to CEO Bob Apple speak at the Deutsche Bank conference and wanted to pass along a few pieces…
Read more…

Antares: AMAG Issues Guidance on Timing of Subcutaneous Makena (ATRS, Buy, $1/05)

I recently wrote a report on Antares entitled Makena has the Potential to Make a Very Significant Contribution to EPS  that…
Read more…

Antares: An Outstanding Product Pipeline Promises Dramatic Growth Through 2022 (ATRS, Buy, $0.92)

Investment Thesis in Brief

If you like numbers, you will like this report. It is a very detailed analysis of the…
Read more…

Antares: Makena Has the Potential to Make a Very Significant Contribution to EPS (ATRS, $0.85. Buy)

Investment Thesis
Investment Overview

The launch of Otrexup has been extremely disappointing in contrast to my high expectations. Medac launched a competitive…
Read more…

Antares: Disappointing News on AB Rated Version of EpiPen (ATRS, $0.95)

Investment Perspective

Teva filed a 6-K regulatory document last night that stated: “Teva received a complete response letter on February 23, 2016 relating…
Read more…

Antares: Undeterred by the Poor Stock Performance I Continue to Pound the Table (ATRS. Buy, $1.30)

Upcoming Catalysts

This is a detailed note updating my thinking on Antares and discussing how I come up with my 2017…
Read more…

Antares: An Update on My Investment Thinking (ATRS, Buy, $1.33)

Investment Thesis

This has been a very disappointing year for Antares investors; the stock closed at $2.57 on December 31, 2014…
Read more…

Antares: The Stock Price Does Not Reflect the Fundamentals (ATRS, $1.60, Buy)

Introduction

Antares recently updated its corporate presentation on their website. .There were several slides in the presentation that reinforce my confidence…
Read more…

Quick Take on Antares Following 2Q, 2015 Conference Call (ATRS, Buy, $2.10)

Investment Opinion

Antares stock has been pummeled by the “so far” disappointing launch of Otrexup and uncertainty as to when or…
Read more…

Antares: One of My Top Stock Picks for 2015 and 2016 (ATRS, Buy, $2.40, For Paid Subscribers)

Introduction to Report

One of my assets is also one of my biggest drawbacks. When I am writing on a Company…
Read more…

Comments on Agenus and Antares

SmithOnStocks Mailbox
About the Mailbox:

My mailbox comments are brief articles on stocks in which I am involved. These can come from…
Read more…

Comments on Antares, Kite Pharma and Northwest Biotherapeutics

SmithOnStocks Mailbox
About the Mailbox:

My mailbox comments are brief articles on stocks in which I am involved. These can come from…
Read more…

Comments on Antares, Agenus, Cytokinetics, Discovery Laboratories and ZS Pharma

SmithOnStocks Mailbox
April 28, 2015
A Quick Take on Recent Events
If you have a question for the mailbox, contact me.
Purpose of this…
Read more…

Antares: Teva Offer to Buy Mylan Should Have No Effect on Launch of AB Rated Generic to EpiPen (ATRS, $2.76, Buy)

Overview

Subsequent to my posting of my recent update on Antares, I have seen that Teva has made an offer to…
Read more…

Antares: Detailed Sales and Earnings Projections for 2015 and 2016 (ATRS, Buy, $2.77, subscription required)

Investment Thesis
I continue with my long standing recommendation on Antares. Last year was a disappointing year for the stock, but…
Read more…

Antares Pharmaceuticals: Highlights of Presentation at JP Morgan Conference (ATRS, $2.36. Buy)

Investment Overview

Antares has hit a somewhat dis-settling stretch as Otrexup prescriptions have recently flattened and the FDA recommended that additional…
Read more…

Delay in Quick Shot Testosterone Clinical Program is Not a Major Setback for the Stock (ATRS, Buy, $2.53)

Antares sent out a press release today about a new development in the Quick Shot Testosterone phase 3 program. The Company…
Read more…

Antares: Responding to Two Questions on Teva’s AB Rated Competitor to EpiPen (ATRS, Buy, $2.44)

Purpose of the Blog

I very much appreciate questions and feedback from subscribers to my website. I have had two recent…
Read more…

Antares: Highlights of CEO’s Presentation at Piper Jaffray Conference (ATRS, Buy, $2.46)

Overview

I tuned in to the Antares presentation at the Piper Jaffrey conference on December 2, 2014 to listen to what…
Read more…

Antares: 2015 Could Be the Breakout Year for the Stock (ATRS, $2.24, Buy)

I project 2015 sales of Otrexup at $22 million; if so, it would be generating profit in the latter half…
Read more…

Antares: Thoughts on FDA Briefing Documents for September 17th Advisory Committee Meeting on Testosterone Replacement Products (ATRS, $2.14, Buy)

The FDA does not appear to be concerned about cardiovascular risk with testosterone replacement products so this is a major…
Read more…

Antares Pharmaceuticals: An Update on Key Issues (ATRS, Buy, $2.14)

Investment Thesis

Antares (ATRS) common has been hit with a storm of concerns that has caused the stock to decline from…
Read more…

Antares; My View of How Otrexup and Medac’s New Product Rasuvo May Compete (ATRS, Buy, $2.54)

Investors Are Concerned About Rasuvo’s Impact on Otrexup

Investors have been concerned about the potential effect on Otrexup if the private…
Read more…

Antares: More On Paul Wotton’s Departures as CEO (ATRS, Buy, $2.77)

This is a follow-up on Paul Wotton’s decision to leave his position as CEO of Antares (ATRS) to become CEO…
Read more…

Antares: Thoughts on the Resignation of the CEO (ATRS, $2.76, Buy)

The resignation of Paul Wotton as CEO of Antares came as a surprise to me and I think most other…
Read more…

Antares: Although it is Still Early, I Think That Otrexup Launch is Going Very Well (ATRS, Buy, $2.93, Paid subscribers)

Investment Thesis

The broad based business model of Antares results in its receiving revenues from numerous products that are marketed by…
Read more…

Thoughts on the Market Correction in Biotechnology Stocks

This Has Been a Tough Correction

The recent sharp market correction and rotation out of growth stocks like biotechnology and technology…
Read more…

Antares (ATRS, Buy, $4.00) Why I Think That the Otrexup Launch Will Be A Success (Paid Subscribers Only)

Recent Price Behavior

Antares’ (ATRS) price has drifted down since the approval of Otrexup for the treatment of rheumatoid arthritis and…
Read more…

San Francisco Trip Is the Basis for a Preview of 2014 (Subscribers Only)

What SmithOnStocks Is All About
It is traditional at the start of the year to go over stock picks for the…
Read more…

Antares: Thoughts on the Upcoming Otrexup Launch (ATRS, $3.64)

Investment Thesis
Antares is preparing to launch Otrexup in January 2014; it is the first product it has ever introduced and…
Read more…

Antares: An In-Depth Look at Otrexup and Re-iteration of My Buy Recommendation (ATRS: $4.45) (Paid Subscribers Only)

Investment Overview and Thesis
Antares has carved out an interesting niche in the pharmaceutical industry through building a drug delivery business…
Read more…

SmithOnStocks Opines on Stocks May 19, Edition

One Approach for Investing in Emerging Biotechnology Stocks
I write on biotechnology and pharmaceutical companies of all sizes, but I have…
Read more…